Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

DC Vaccination in CML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02543749
Recruitment Status : Recruiting
First Posted : September 7, 2015
Last Update Posted : January 31, 2019
Sponsor:
Information provided by (Responsible Party):
Jörg Westermann, MD, Charite University, Berlin, Germany

Brief Summary:

The aim of this phase I/II trial is induction of anti leukemic T cell immunity in a clinical situation of "minimal residual disease". This might be a strategy to immunologically eradicate the residual leukemia cells. Patients to be included are chronic phase bcr/abl+ CML (chronic myeloid leukemia) patients in stable cytogenetic and/or molecular remission.

These patients can be included if they have:

  1. not achieved a CMR (complete molecular response) or
  2. achieved bcr/abl < 10% on qPCR (quantitative polymerase chain reaction) (=MCyR) (Major cytogenic Response), but less than a CCyR (complete cytogenic Response).

Autologous DC (Dendritic cells), generated under GMP (Good manufacturing conditions) conditions, are used as a vaccine. These DC constitutively express all putative tumor antigens. In order to ensure sufficient presentation of distinct CML-related antigens, particularly in good responders to TKIs, DC are additionally pulsed with peptides from bcr/abl, WT-1 (Wilms Tumor Protein) and proteinase-3. Monitoring of T cell reactivity against these peptides can then serve as surrogate marker for anti leukemic immunity induced by the vaccine. Vaccination is performed with 10^7 DC i.d. (intra dermal) in weeks 1, 3, 5, 8, 11, 14, 17, 20, 23 and 26. KLH (keyhole limpet hemocyanin) is used as an adjuvant for vaccine preparations in weeks 3, 5 and 8 (and 11).


Condition or disease Intervention/treatment Phase
Myeloid Leukemia, Chronic Biological: DC vaccine Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dendritic Cells as Autologous Vaccine in Patients With Chronic Myeloid Leukemia
Study Start Date : July 2014
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : January 2022


Arm Intervention/treatment
Experimental: DC vaccine

Autologous DC pulsed with leukemia-associated peptides+adjuvant.

Ten vaccinations over 26 weeks with 10 x 106 freshly thawed DC Intradermal injections (1-2 ml volume)

Biological: DC vaccine
Autologous DC pulsed with leukemia-associated peptides+adjuvant




Primary Outcome Measures :
  1. DC toxicity Parameters using CTC (Common toxicity criteria) [ Time Frame: 30 weeks ]
    Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 (Treatment: long-term vaccination with peptide-pulsed autologous DC in patients with chronic phase CML who have persistent residual cytogenetic and/or molecular disease after at least 18 months therapy with a tyrosine kinase Inhibitor)


Secondary Outcome Measures :
  1. Molecular/cytogenetic Response under vaccination as measured by qPCR for bcr/abl in % IS (International scale) [ Time Frame: 30 weeks ]
  2. T-cell Response: Antigen specific T-cell Response in % CD8+ T-cells for bcr/abl [ Time Frame: 30 weeks ]
  3. T-cell Response: Antigen specific T-cell Response in % CD4+ T-cells for bcr/abl [ Time Frame: 30 weeks ]
  4. T-cell Response: Antigen specific T-cell Response in % CD8+ T-cells for WT-1 (only in HLA-A2+ patients) [ Time Frame: 30 weeks ]
  5. T-cell Response: Antigen specific T-cell Response in % CD8+ T-cells for Proteinase 3 (only in HLA-A2+ patients) [ Time Frame: 30 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with bcr/abl-positive CML in stable cytogenetic / molecular remission after at least 18 months therapy with tyrosine kinase Inhibitors (TKI). The following groups of patients will be included:

    • complete cytogenetic remission (CCyR), but stable detection of bcr/abl-transcript on qPCR (at least on two different time points over a period of at least 6 months). A stable molecular remission is assumed, if the difference between the qPCR values does not exceed a factor 5 (< 0,5log).
    • No CCyR, but qPCR for bcr/abl transcript < 10% (= MCyR (Major cytogenetic Response)) after at least 24 months on 2nd generation TKI therapy.
  2. Treatment with a TKI inhibitor and an additional anti leukemic drug is no exclusion criterion.
  3. Age 18-80 years
  4. Performance status of 0 or 1 according to WHO index or Karnofsky index >70 %
  5. Life expectancy > 18 months
  6. Hematological function should be at least partially conserved (platelets count >50.000/ μl, Hb > 8g/dl)
  7. written informed consent
  8. No breast feeding
  9. if of childbearing potential, negative pregnancy test (serum/urine ß- HCG ( human chorionic gonadotropin )) and willingness to use highly effective contraceptive methods (Pearl Index <1, e.g.: birth control pill, loop, hormone implant, transdermal hormone patch, a combination of two barrier methods [condom and vaginal diaphragm] sterilisation or sexual abstinence) for the study duration and thereafter as long as under treatment with antileukemic drugs

Exclusion Criteria:

  1. Clinically relevant autoimmune disorders
  2. Immunodeficiency syndromes
  3. Known allergy to GM-CSF (granulocyte macrophage colony-stimulating factor), TNF-α (Tumor necrosis factor Alpha) , IL-4 (interleukine 4) or KLH (keyhole limpet hemocyanin)
  4. Pregnancy (absence confirmed by serum/urine ß-HCG) or breastfeeding
  5. Women of childbearing age without highly effective contraception
  6. Active infectious disease requiring treatment
  7. Continuous therapy with corticosteroids or other immunosuppressive drugs
  8. Severe psychiatric disorders
  9. Organ dysfunction:

    • Thrombin Time / Partial Thromboplastin Time > 1,5 x upper normal limit
    • creatinine > 2,0 mg/ml
    • Bilirubin > 3,0 mg/ml, ALAT/ASAT (Alanine aminotransferase/ aspartate aminotransferase) > 3x upper normal limit
    • pulmonary disfunction (dyspnea at rest or with minimal exertion)
    • clinically relevant coronary heart disease or ventricular arrhythmia, congestive heart failure > grade II NYHA (New York Heart Association)
  10. Persons who are detained officially or legally to an official institute
  11. Subjects for whom there is concern about compliance with the protocol procedures
  12. Present History of substance abuse (drug or alcohol) or any other factor (e.g., serious psychiatric condition) that could limit the subject's ability to comply with study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02543749


Contacts
Layout table for location contacts
Contact: J. Westermann, Prof. Dr. +49-30-450-553141 joerg.westermann@charite.de
Contact: A. Pezzutto, Prof. Dr. +49-30-450-553431 antonio.pezzutto@charite.de

Locations
Layout table for location information
Germany
Charité - University Medicine Berlin Recruiting
Berlin, Germany, 13353
Contact: Jörg Westermann, Prof. Dr.    +49-30-450-553141    joerg.westermann@charite.de   
Klinikum Bremen Mitte Not yet recruiting
Bremen, Germany, 28177
Contact: Bernd Hertenstein, Prof. Dr.         
Sponsors and Collaborators
Charite University, Berlin, Germany
Investigators
Layout table for investigator information
Principal Investigator: J. Westermann, Prof. Dr. Charite University, Berlin, Germany

Layout table for additonal information
Responsible Party: Jörg Westermann, MD, Representative of the sponsor, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier: NCT02543749     History of Changes
Other Study ID Numbers: CSTI571ADE60
2006-006962-41 ( EudraCT Number )
First Posted: September 7, 2015    Key Record Dates
Last Update Posted: January 31, 2019
Last Verified: January 2019
Keywords provided by Jörg Westermann, MD, Charite University, Berlin, Germany:
CML
DC vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Neoplasms
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs